Koenraad Blot
Keine laufenden Positionen mehr
Profil
Koenraad Blot worked as an Executive Director of Clinical Research at Theratechnologies, Inc., Head of Medical Affairs and Clinical Operations at Pfizer Inc., and Chief Medical Officer at TiGenix NV and elbion NV.
He holds a doctorate from Ghent University and an undergraduate degree from the University of Antwerp.
Ehemalige bekannte Positionen von Koenraad Blot
| Unternehmen | Position | Ende |
|---|---|---|
| TIGENIX NV | Technik-/Wissenschafts-/F&E-Leiter | - |
| THERATECHNOLOGIES INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| PFIZER, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Koenraad Blot
| Ghent University | Doctorate Degree |
| University of Antwerp | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
